Form 8-K - Current report:
SEC Accession No. 0001193125-25-016455
Filing Date
2025-01-30
Accepted
2025-01-30 09:03:26
Documents
19
Period of Report
2025-01-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d914999d8k.htm   iXBRL 8-K 33105
2 EX-4.1 d914999dex41.htm EX-4.1 71004
3 EX-5.1 d914999dex51.htm EX-5.1 11056
4 EX-10.1 d914999dex101.htm EX-10.1 175241
5 EX-99.1 d914999dex991.htm EX-99.1 10630
9 GRAPHIC g914999dsp5.jpg GRAPHIC 6653
10 GRAPHIC g914999dsp6.jpg GRAPHIC 3605
  Complete submission text file 0001193125-25-016455.txt   524693

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA eltx-20250129.xsd EX-101.SCH 2877
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE eltx-20250129_lab.xml EX-101.LAB 18737
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eltx-20250129_pre.xml EX-101.PRE 11725
22 EXTRACTED XBRL INSTANCE DOCUMENT d914999d8k_htm.xml XML 3796
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 25571318
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)